Summary
This multicenter retrospective study developed and validated a simple prognostic model for patients with chemoresistant urothelial carcinoma receiving pembrolizumab immunotherapy. The model stratified patients into low-, intermediate-, and high-risk groups based on four clinicopathological variables, with low-risk patients showing substantially superior overall survival (not yet reached vs. 2.3 months in high-risk group) and response rates (48.3% vs. 10.5%). The validated model demonstrated clinical utility for patient counselling and trial design in this immunotherapy setting.
UK applicability
The findings are clinically relevant to UK oncology practice, as pembrolizumab is used in the UK for advanced urothelial cancer treatment. However, the cohort was Japan-based and may reflect differences in baseline patient characteristics, treatment pathways, and healthcare contexts compared to UK populations; independent validation in UK or European cohorts would strengthen applicability.
Key measures
Overall survival (OS) by risk group; hazard ratios (95% confidence intervals); objective response rates; median OS times in discovery (463 patients) and validation (292 patients) cohorts
Outcomes reported
The study developed and validated a multivariate prognostic model predicting overall survival and objective response rates in patients with chemoresistant urothelial carcinoma treated with pembrolizumab. Risk stratification was based on performance status, site of metastasis, haemoglobin levels, and neutrophil-to-lymphocyte ratio.
Topic tags
Dig deeper with Pulse AI.
Pulse AI has read the whole catalogue. Ask about this record, its theme, or how the findings apply to UK farming and policy — every answer cites the underlying studies.